Daisuke Yamada

Daisuke Yamada

Auto-generated profile, based on publicly available information

Daisuke Yamada

Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in eneuro
Verified
Journal Article
Open access
PDF file
ITIkuo Tomioka
Ikuo Tomioka
HIHidetoshi Ishibashi
Hidetoshi Ishibashi
EMEiko N. Minakawa
Eiko N. Minakawa
HMHideyuki H. Motohashi
Hideyuki H. Motohashi
OTOsamu Takayama
Osamu Takayama
KSKazuhiko Seki
Kazuhiko Seki
Age-associated neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and the polyglutamine (polyQ) diseases, are becoming prevalent as a consequence of elongation of the human lifespan. Although various rodent models have been developed to study and overcome these diseases, they have limitations in their translational research utility owing to differences from humans in brain structure and function and in drug metabolism. Here, we generated a transgenic marmoset model of the polyQ diseases, showing progressive neurological symptoms including motor impairment. Seven transgenic marmosets were produced by lentiviral introduction of the human ataxin 3 gene with 120 CAG repeats encoding an expanded polyQ stretch. Although all offspring showed no neurological symptoms at birth, three marmosets with higher transgene expression developed neurological symptoms of varying degrees at 3–4 months after birth, followed by gradual decreases in body weight gain, spontaneous activity, and grip strength, indicating time-dependent disease progression. Pathological examinations revealed neurodegeneration and intranuclear polyQ protein inclusions accompanied by gliosis, which recapitulate the neuropathological features of polyQ disease patients. Consistent with neuronal loss in the cerebellum, brain MRI analyses in one living symptomatic marmoset detected enlargement of the fourth ventricle, which suggests cerebellar atrophy. Notably, successful germline transgene transmission was confirmed in the second-generation offspring derived from the symptomatic transgenic marmoset gamete. Because the accumulation of abnormal proteins is a shared pathomechanism among various neurodegenerative diseases, we suggest that this new marmoset model will contribute toward elucidating the pathomechanisms of and developing clinically applicable therapies for neurodegenerative diseases.

12 August 2009 in Neuropsychopharmacology
Verified
Journal Article
Closed access
DYDaisuke Yamada
Daisuke Yamada
KZKo Zushida
Ko Zushida
KWKeiji Wada
Keiji Wada
MSMasayuki Sekiguchi
Masayuki Sekiguchi

12 February 2014 in Neuropsychopharmacology
Verified
Journal Article
Closed access
DYDaisuke Yamada
Daisuke Yamada
JTJiro Takeo
Jiro Takeo
PKPeter Koppensteiner
Peter Koppensteiner
KWKeiji Wada
Keiji Wada
MSMasayuki Sekiguchi
Masayuki Sekiguchi

6 September 2011 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
IHI‐Ching Hou
I‐Ching Hou
CSChihiro Suzuki
Chihiro Suzuki
NKNorimasa Kanegawa
Norimasa Kanegawa
AOAyako Oda
Ayako Oda
AYAyako Yamada
Ayako Yamada
KOKousaku Ohinata
Kousaku Ohinata
J. Neurochem. (2011) 119, 785–790. β‐Lactotensin (His‐Ile‐Arg‐Leu) is a bioactive peptide derived from bovine milk β‐lactoglobulin, acting as a natural agonist for neurotensin receptors. We found that β‐lactotensin exhibited anxiolytic‐like activity in an elevated plus‐maze test after its intraperitoneal (i.p.) administration in mice. β‐Lactotensin was also orally active. The anxiolytic‐like activity of β‐lactotensin after i.p. administration was blocked by levocabastine, an antagonist for the neurotensin NTS2 receptor. β‐Lactotensin had anxiolytic‐like activity in wild‐type but not Ntsr2‐knockout mice. β‐Lactotensin increased intracellular Ca2+ flux in glial cells derived from wild‐type mice but not Ntsr2 knockout mice. These results suggest that β‐lactotensin acts as an NTS2 receptor agonist having anxiolytic‐like activity. The anxiolytic‐like activity of β‐lactotensin was also blocked by SCH23390 and SKF83566, antagonists for dopamine D1 receptor, but not by raclopride, an antagonist for D2 receptor. Taken together, β‐lactotensin may exhibit anxiolytic‐like activity via NTS2 receptor followed by D1 receptor.

11 July 2007 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
RYRena Yamauchi
Rena Yamauchi
EWEtsuko Wada
Etsuko Wada
SKSari Kamichi
Sari Kamichi
DYDaisuke Yamada
Daisuke Yamada
HMHiroshi Maeno
Hiroshi Maeno
KWKeiji Wada
Keiji Wada

24 October 2018 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MIMasayuki Itoh
Masayuki Itoh
MYMariko Yamashita
Mariko Yamashita
MKMasaki Kaneko
Masaki Kaneko
HOHiroyuki Okuno
Hiroyuki Okuno
MAManabu Abe
Manabu Abe
THTakashi Hayashi
Takashi Hayashi
Synaptic AMPAR expression controls the strength of excitatory synaptic transmission and plasticity. An excess of synaptic AMPARs leads to epilepsy in response to seizure-inducible stimulation. The appropriate regulation of AMPARs plays a crucial role in the maintenance of the excitatory/inhibitory synaptic balance; however, the detailed mechanisms underlying epilepsy remain unclear. Our previous studies have revealed that a key modification of AMPAR trafficking to and from postsynaptic membranes is the reversible, posttranslationalS-palmitoylation at the C-termini of receptors. To clarify the role of palmitoylation-dependent regulation of AMPARsin vivo, we generated GluA1 palmitoylation-deficient (Cys811 to Ser substitution) knock-in mice. These mutant male mice showed elevated seizure susceptibility and seizure-induced neuronal activity without impairments in synaptic transmission, gross brain structure, or behavior at the basal level. Disruption of the palmitoylation site was accompanied by upregulated GluA1 phosphorylation at Ser831, but not at Ser845, in the hippocampus and increased GluA1 protein expression in the cortex. Furthermore, GluA1 palmitoylation suppressed excessive spine enlargement above a certain size after LTP. Our findings indicate that an abnormality in GluA1 palmitoylation can lead to hyperexcitability in the cerebrum, which negatively affects the maintenance of network stability, resulting in epileptic seizures.SIGNIFICANCE STATEMENTAMPARs predominantly mediate excitatory synaptic transmission. AMPARs are regulated in a posttranslational, palmitoylation-dependent manner in excitatory synapses of the mammalian brain. Reversible palmitoylation dynamically controls synaptic expression and intracellular trafficking of the receptors. Here, we generated GluA1 palmitoylation-deficient knock-in mice to clarify the role of AMPAR palmitoylationin vivo. We showed that an abnormality in GluA1 palmitoylation led to hyperexcitability, resulting in epileptic seizure. This is the first identification of a specific palmitoylated protein critical for the seizure-suppressing process. Our data also provide insight into how predicted receptors such as AMPARs can effectively preserve network stability in the brain. Furthermore, these findings help to define novel key targets for developing anti-epileptic drugs.